University of California, Davis
One Shields Avenue
About University of California, DavisAmong the nation's leading public universities, UC Davis is unique in having top-caliber programs in virtually all fields touched by biotechnology-agriculture, veterinary and human medicine, biology, environmental sciences and biomedical engineering. Close to half of the campus's 1,500 faculty members are involved in the life sciences, positioning UC Davis to become a world leader in the post-genome era of scientific research. The university has launched a genomics intiatiative (http://www.genomics.ucdavis.edu/), including a soon-to-be constructed $95 million Genome and Biomedical Sciences Building. In particular, the university is developing leading programs in functional genomics, proteomics and bioinformatics.
UC Davis biology graduates are sought after by biotechnology companies. The campus has been nation's top producer of biological-science doctoral degrees nearly every year since the National Research Council began keeping track in 1987. Moreover, those Ph.D. programs are highly regarded, tying for 6th among public institutions in U.S. News and World Report's 2001 ranking. Graduate programs in plant biology and ecology, evolution and behavior are considered the nation's best (The Gourman Report and Bulletin of the Ecological Society of America, respectively).
UC Davis ranks first in recipients of bioscience grants from the National Science Foundation.
The Division of Biological Sciences (http://www.dbs.ucdavis.edu/) offers nine majors to more than 3,600 undergraduate students and administers 12 graduate groups for more than 500 students. The division is organized into five academic sections: Evolution and Ecology; Microbiology; Neurobiology, Physiology and Behavior; Molecular and Cellular Biology; and Plant Biology.
Last Updated 1-8-01
292 articles about University of California, Davis
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
IO Biotech announced today that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company’s investigational immune-modulating cancer vaccine.
As the monkeypox outbreak continues in the U.S. and abroad, researchers and health officials race to test drugs against the disease. For that and more research stories, continue reading.
The Lung Cancer Mutation Consortium announces the initiation of trial sites at USC Norris Cancer Center, University of California-Davis, University of Michigan, and University of Washington for its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer, examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.
Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases
Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announcedthat it will host a virtual R&D day event on Thursday, May 20, 2021, at 11:00 am EDT / 17:00 CEST.
BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases
BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers.
A new nonhuman primate Alzheimer’s disease model developed by researchers from University of California, Davis and elsewhere could open the door to getting better therapies into human testing.
Company will sponsor sequencing and assembly at UC Davis to produce reference-grade genomes for several ecologically important organisms in the state of California
Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma
Trial will replace currently used chemotherapy conditioning with apamistamab-I-131, Actinium's targeted conditioning ARC, to selectively eliminate lymphoma cancer cells and stem cells to enable engraftment of stem cell gene therapy
Orgenesis announces addition of University of California, Davis, to its point of care network; UC Davis Health to utilize Orgenesis’ point of care platform for the development, commercialization and supply of cell and gene therapy products
First collaboration project focused on developing and commercializing lentiviral manufacturing system
Research from the University of California, Davis, finds episodes of extremely hot weather lead to declines in market value.
Evolve BioSystems And The Regents Of The University Of California Jointly File Patent Infringement Complaint Against Abbott Laboratories Regarding Infant Probiotic
Evolve BioSystems and the Regents of the University of California have jointly filed and served a patent infringement complaint against Abbott Laboratories.
University of California, Davis Study Shows up to 98% Reduction of Intestinal Inflammation Markers Linked to Colic, Eczema, Asthma and Diabetes
UC Davis Health Images First U.S. Patient Using Ultra-High Resolution CT with Canon Medical’s Aquilion Precision
Initial Global Use of the Aquilion Precision has Demonstrated Significantly Increased Visibility of Small Anatomical Structures
The study will focus on whether or not treatment with progesterone will counter-act the first dose of a chemical-induced abortion medication.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
December 28 Research Roundup: Super Leukemia Drug, Synthetic Antibiotics, How Marijuana Changes t...
12/28/2018There are plenty of great scientific research stories out this week. Here’s a look at just a few of them, from Northwestern, UC Davis, Cornell, Duke, and others.
First human trial to demonstrate the favorable vascular effects of mango consumption
Educational institutions, even at the high school level, are creating specialized biotechnology training programs to satisfy the growth they see within the biotech industry.
Dow AgroSciences and University of California-Davis Team up with Consortium to Advance Orphan African Crops
The progress made by the AOCC is being highlighted at a workshop during the International Plant & Animal Genome XXVI Conference taking place in San Diego, Jan. 13-17, 2018.
Front Range Biosciences Partners with University of California, Davis for Cannabis Genomics Research
Front Range Biosciences is pleased to announce that the Company has launched a genomics research initiative with the UC Davis,to advance understanding of cannabis for medical and nutraceutical uses.